| abstract |
FIELD: medicine; pharmaceuticals.SUBSTANCE: group of inventions relates to the chemical-pharmaceutical industry and is a modified release pharmaceutical composition containing two types of modified release particles, where each particle contains: 5–20 % by weight of anti-methanogenic statin; 50–70 % by weight of microcrystalline cellulose; 1–10 % by weight of copovidone; 0.1–3.0 wt. % silicon dioxide; 0.1–3.0 wt. % magnesium stearate; 1–10 wt. % of crospovidone; and 10–20 % by weight of enterosoluble polymer; where the first type of modified release particles comprises a first enteric polymer which is soluble at a pH of about 5.5, and the second type of particles with modified release contains a second enteric polymer, which is dissolved at pH of about 7.0. Invention also relates to a method of treating IBS associated with constipation predominance.EFFECT: group of inventions provides specific delivery of antimetanogenic statins to the methanoligenation site while preventing or reducing systemic exposure thereof.21 cl, 20 dwg, 8 tbl, 6 ex |